Latest news for HAEMATO (OTC:HAAGF) Stock

HAEMATO AG is a Germany based pharmaceutical company. It provides pharmaceuticals for the care of chronically ill people. The firm is engaged in the sale of generic and EU (European countries) import drugs. It is focused on patented and non-patented medicinal products. The company product portfolio includes human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), neurology, oncology, rheumatology, and urology. Geographically, it operates only in Germany.

HAEMATO AG

<p>Dick's Sporting Goods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) will release its quarterly earnings report on Tuesday, 2024-11-26. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Dick's Sporting Goods to report an <strong>earnings per share</strong> (EPS) of $2.67.</p>
<p>The market awaits Dick's Sporting Goods's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the last quarter, the company reported an EPS beat by $0.54, leading to a 2.69% drop in the share price on the subsequent day.</p>
<p>Here's a look at Dick's Sporting Goods's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>3.83</td>
<td>2.95</td>
<td>3.35</td>
<td>2.45</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>4.37</td>
<td>3.30</td>
<td>3.85</td>
<td>2.85</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-3.0%</td>
<td>-1.0%</td>
<td>-2.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732543276_0_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Dick's Sporting Goods were trading at $210.16 as of November 22. Over the last 52-week period, shares are up 68.61%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<h3>Insights Shared by Analysts on Dick's Sporting Goods</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Dick's Sporting Goods.</p>
<p>The consensus rating for Dick's Sporting Goods is Neutral, derived from 13 analyst ratings. An average one-year price target of $249.15 implies a potential 18.55% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of Ulta Beauty, Chewy and Tractor Supply, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>The consensus outlook from analysts is an Neutral trajectory for Ulta Beauty, with an average 1-year price target of $408.76, indicating a potential 94.5% upside.</li>
<li>As per analysts' assessments, Chewy is favoring an Outperform trajectory, with an average 1-year price target of $34.07, suggesting a potential 83.79% downside.</li>
<li>The consensus among analysts is an Buy trajectory for Tractor Supply, with an average 1-year price target of $299.42, indicating a potential 42.47% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
<p>Within the peer analysis summary, vital metrics for Ulta Beauty, Chewy and Tractor Supply are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dick's Sporting Goods</td>
<td>Neutral</td>
<td>7.75%</td>
<td>$1.28B</td>
<td>12.91%</td>
</tr>
<tr>
<td>Ulta Beauty</td>
<td>Neutral</td>
<td>0.88%</td>
<td>$978.18M</td>
<td>10.87%</td>
</tr>
<tr>
<td>Chewy</td>
<td>Outperform</td>
<td>2.63%</td>
<td>$843.84M</td>
<td>52.96%</td>
</tr>
<tr>
<td>Tractor Supply</td>
<td>Buy</td>
<td>1.65%</td>
<td>$1.29B</td>
<td>10.51%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Dick's Sporting Goods ranks in the middle among its peers for Consensus rating. It is at the top for Revenue Growth, indicating strong performance in this area. The company is in the middle for Gross Profit, suggesting average profitability compared to peers. Dick's Sporting Goods is at the bottom for Return on Equity, showing lower returns relative to its peers.</p>
<h3>Discovering Dick's Sporting Goods: A Closer Look</h3>
<p>Dick's Sporting Goods retails athletic apparel, footwear, and equipment for sports. Dick's operates digital platforms, about 725 stores under its namesake brand (including outlet stores and House of Sport), and about 130 specialty stores under the Golf Galaxy and Public Lands nameplates. Dick's carries private-label merchandise and national brands such as Nike, The North Face, Under Armour, Callaway Golf, and TaylorMade. Based in the Pittsburgh area, Dick's was founded in 1948 by the father of current executive chairman and controlling shareholder Edward Stack.</p>
<h3>Understanding the Numbers: Dick's Sporting Goods's Finances</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Dick's Sporting Goods displayed positive results in 3 months. As of 31 July, 2024, the company achieved a solid revenue growth rate of approximately <strong>7.75%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Dick's Sporting Goods's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>10.43%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>12.91%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Dick's Sporting Goods's ROA excels beyond industry benchmarks, reaching <strong>3.69%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Dick's Sporting Goods's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>1.5</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<p><a href="https://www.benzinga.com/quote/DKS/earnings"><strong>To track all earnings releases for Dick's Sporting Goods visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

Dick's Sporting Goods's Earnings: A Preview

<p>Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) has outperformed the market over the past 15 years by 9.98% on an annualized basis producing an average annual return of 21.81%. Currently, Live Nation Entertainment has a market capitalization of $32.51 billion. </p>
<p><strong>Buying $100 In LYV:</strong> If an investor had bought $100 of LYV stock 15 years ago, it would be worth <strong>$1,959.36</strong> today based on a price of $141.00 for LYV at the time of writing.</p>
<h3>Live Nation Entertainment's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732543276_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


News

Trading Ideas

Here's How Much You Would Have Made Owning Live Nation Entertainment Stock In The Last 15 Years

Nano Nuclear Energy Secures $60M Private Placement To Advance Portable Nuclear Microreactor Technologies, Boost Cash Position To Over $120M, And Accelerate Growth Towards Initial Revenue Generation

<p>Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) has outperformed the market over the past 5 years by 23.92% on an annualized basis producing an average annual return of 37.56%. Currently, Trade Desk has a market capitalization of $64.57 billion. </p>
<p><strong>Buying $100 In TTD:</strong> If an investor had bought $100 of TTD stock 5 years ago, it would be worth <strong>$492.52</strong> today based on a price of $130.82 for TTD at the time of writing.</p>
<h3>Trade Desk's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732543271_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much $100 Invested In Trade Desk 5 Years Ago Would Be Worth Today

<p>Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) is gearing up to announce its quarterly earnings on Tuesday, 2024-11-26. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Analog Devices will report an <strong>earnings per share</strong> (EPS) of $1.64.</p>
<p>The announcement from Analog Devices is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Past Earnings Performance</h3>
<p>The company's EPS beat by $0.08 in the last quarter, leading to a 2.46% drop in the share price on the following day.</p>
<p>Here's a look at Analog Devices's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.50</td>
<td>1.26</td>
<td>1.71</td>
<td>2</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.58</td>
<td>1.40</td>
<td>1.73</td>
<td>2.01</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732543266_0_0.png" alt="eps graph" /></p>
<h3>Tracking Analog Devices's Stock Performance</h3>
<p>Shares of Analog Devices were trading at $214.59 as of November 22. Over the last 52-week period, shares are up 17.13%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Insights Shared by Analysts on Analog Devices</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Analog Devices.</p>
<p>A total of 3 analyst ratings have been received for Analog Devices, with the consensus rating being Neutral. The average one-year price target stands at $234.33, suggesting a potential 9.2% upside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Intel, Micron Technology and Marvell Tech, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Intel is maintaining an Neutral status according to analysts, with an average 1-year price target of $23.33, indicating a potential 89.13% downside.</li>
<li>The prevailing sentiment among analysts is an Buy trajectory for Micron Technology, with an average 1-year price target of $139.26, implying a potential 35.1% downside.</li>
<li>The consensus outlook from analysts is an Buy trajectory for Marvell Tech, with an average 1-year price target of $95.21, indicating a potential 55.63% downside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
<p>The peer analysis summary outlines pivotal metrics for Intel, Micron Technology and Marvell Tech, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Analog Devices</td>
<td>Neutral</td>
<td>-24.84%</td>
<td>$1.31B</td>
<td>1.11%</td>
</tr>
<tr>
<td>Intel</td>
<td>Neutral</td>
<td>-6.17%</td>
<td>$2.00B</td>
<td>-15.50%</td>
</tr>
<tr>
<td>Micron Technology</td>
<td>Buy</td>
<td>93.27%</td>
<td>$2.74B</td>
<td>1.99%</td>
</tr>
<tr>
<td>Marvell Tech</td>
<td>Buy</td>
<td>-5.07%</td>
<td>$587.60M</td>
<td>-1.35%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Analog Devices ranks at the bottom for Revenue Growth with a negative percentage, while one peer shows a significant positive growth. Analog Devices also ranks at the bottom for Gross Profit, with one peer having a higher gross profit. For Return on Equity, Analog Devices is in the middle compared to its peers. Overall, Analog Devices is positioned lower compared to its peers in terms of financial performance metrics.</p>
<h3>Discovering Analog Devices: A Closer Look</h3>
<p>Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.</p>
<h3>Analog Devices: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Analog Devices faced challenges, resulting in a decline of approximately <strong>-24.84%</strong> in revenue growth as of 31 July, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Analog Devices's net margin excels beyond industry benchmarks, reaching <strong>16.96%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Analog Devices's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>1.11%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.8%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Analog Devices's debt-to-equity ratio is below the industry average at <strong>0.23</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/ADI/earnings"><strong>To track all earnings releases for Analog Devices visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Preview: Analog Devices's Earnings

<p>Chewy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">8</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Chewy, revealing an average target of $34.07, a high estimate of $40.00, and a low estimate of $24.00. Marking an increase of 21.68%, the current average surpasses the previous average price target of $28.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732543267_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Chewy. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Justin Kleber</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Lee Horowitz</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$28.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Curtis Nagle</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Trevor Young</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Steven Zaccone</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Bill Kerr</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Buy</td>
<td>$38.00</td>
<td>-</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$35.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$33.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Lauren Schenk</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$33.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Steven Shemesh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Trevor Young</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$34.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$30.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Curtis Nagle</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$24.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Mark Mahaney</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$29.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Chewy. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Chewy compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Chewy's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>To gain a panoramic view of Chewy's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CHWY/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Chewy analyst ratings.</strong></a></p>
<h2>All You Need to Know About Chewy</h2>
<p>Chewy is the largest e-commerce pet care retailer in the US, generating $11.2 billion in 2023 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a stand-alone company in 2019 after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods, like crates, leashes, and bowls.</p>
<h3>Chewy: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Revenue Growth:</strong> Chewy's revenue growth over a period of 3 months has been noteworthy. As of 31 July, 2024, the company achieved a revenue growth rate of approximately <strong>2.63%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Chewy's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>10.46%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Chewy's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>52.96%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Chewy's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>9.49%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.06</strong>.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

CHWY

Decoding 15 Analyst Evaluations For Chewy

<p>ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) has outperformed the market over the past 10 years by 10.96% on an annualized basis producing an average annual return of 22.1%. Currently, ON Semiconductor has a market capitalization of $30.02 billion. </p>
<p><strong>Buying $1000 In ON:</strong> If an investor had bought $1000 of ON stock 10 years ago, it would be worth <strong>$7,297.69</strong> today based on a price of $70.50 for ON at the time of writing.</p>
<h3>ON Semiconductor's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732543266_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much $1000 Invested In ON Semiconductor 10 Years Ago Would Be Worth Today

<p>Teledyne Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDY#NYSE">TDY</a>) has outperformed the market over the past 20 years by 6.42% on an annualized basis producing an average annual return of 14.79%. Currently, Teledyne Technologies has a market capitalization of $22.40 billion. </p>
<p><strong>Buying $100 In TDY:</strong> If an investor had bought $100 of TDY stock 20 years ago, it would be worth <strong>$1,585.87</strong> today based on a price of $480.59 for TDY at the time of writing.</p>
<h3>Teledyne Technologies's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732543260_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much You Would Have Made Owning Teledyne Technologies Stock In The Last 20 Years

<p>Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) will release its quarterly earnings report on Tuesday, 2024-11-26. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Dell Technologies to report an <strong>earnings per share</strong> (EPS) of $2.04.</p>
<p>Investors in Dell Technologies are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Performance in Previous Earnings</h3>
<p>The company's EPS beat by $0.18 in the last quarter, leading to a 4.33% increase in the share price on the following day.</p>
<p>Here's a look at Dell Technologies's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.71</td>
<td>1.26</td>
<td>1.73</td>
<td>1.47</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.89</td>
<td>1.27</td>
<td>2.20</td>
<td>1.88</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>4.0%</td>
<td>-18.0%</td>
<td>32.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732543257_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Dell Technologies were trading at $144.21 as of November 22. Over the last 52-week period, shares are up 94.8%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/DELL/earnings"><strong>To track all earnings releases for Dell Technologies visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


DELL

Dell Technologies's Earnings Outlook

<p>Ratings for Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $7.5, a high estimate of $9.00, and a low estimate of $5.00. This current average has decreased by 16.67% from the previous average price target of $9.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732543258_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Rockwell Medical by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$7.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Brandon Folkes</td>
<td>Rodman &amp; Renshaw</td>
<td>Announces</td>
<td>Buy</td>
<td>$5.00</td>
<td>-</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$9.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$9.00</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Rockwell Medical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Rockwell Medical compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Rockwell Medical's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Rockwell Medical's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RMTI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Rockwell Medical analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Rockwell Medical</h2>
<p>Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.</p>
<h3>Key Indicators: Rockwell Medical's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Rockwell Medical's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>19.12%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>5.88%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Rockwell Medical's ROE excels beyond industry benchmarks, reaching <strong>6.32%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Rockwell Medical's ROA excels beyond industry benchmarks, reaching <strong>3.02%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Rockwell Medical's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.49</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


RMTI

What Analysts Are Saying About Rockwell Medical Stock

<p>Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) has outperformed the market over the past 5 years by 28.88% on an annualized basis producing an average annual return of 42.52%. Currently, Dell Technologies has a market capitalization of $103.68 billion. </p>
<p><strong>Buying $1000 In DELL:</strong> If an investor had bought $1000 of DELL stock 5 years ago, it would be worth <strong>$5,878.99</strong> today based on a price of $147.69 for DELL at the time of writing.</p>
<h3>Dell Technologies's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732543255_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$1000 Invested In Dell Technologies 5 Years Ago Would Be Worth This Much Today

Offerings

AMPG

AmpliTech Group Prices $1.4M Registered Direct Offering At $0.92/Share

<p>Burlington Stores (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) is preparing to release its quarterly earnings on Tuesday, 2024-11-26. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Burlington Stores to report an <strong>earnings per share</strong> (EPS) of $1.54.</p>
<p>Anticipation surrounds Burlington Stores's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings Track Record</h3>
<p>Last quarter the company beat EPS by $0.29, which was followed by a 0.4% increase in the share price the next day.</p>
<p>Here's a look at Burlington Stores's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.95</td>
<td>1.04</td>
<td>3.30</td>
<td>0.99</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.24</td>
<td>1.35</td>
<td>3.69</td>
<td>1.10</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>0.0%</td>
<td>2.0%</td>
<td>-2.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732543250_0.png" alt="eps graph" /></p>
<h3>Burlington Stores Share Price Analysis</h3>
<p>Shares of Burlington Stores were trading at $286.17 as of November 22. Over the last 52-week period, shares are up 66.96%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Views on Burlington Stores</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Burlington Stores.</p>
<p>With 11 analyst ratings, Burlington Stores has a consensus rating of Buy. The average one-year price target is $309.36, indicating a potential 8.1% upside.</p>
<h3>Peer Ratings Overview</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of Gap, Abercrombie &amp; Fitch and Boot Barn Holdings, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>The consensus outlook from analysts is an Neutral trajectory for Gap, with an average 1-year price target of $27.8, indicating a potential 90.29% downside.</li>
<li>The consensus among analysts is an Neutral trajectory for Abercrombie &amp; Fitch, with an average 1-year price target of $185.62, indicating a potential 35.14% downside.</li>
<li>For Boot Barn Holdings, analysts project an Buy trajectory, with an average 1-year price target of $171.56, indicating a potential 40.05% downside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
<p>Within the peer analysis summary, vital metrics for Gap, Abercrombie &amp; Fitch and Boot Barn Holdings are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Burlington Stores</td>
<td>Buy</td>
<td>13.37%</td>
<td>$1.06B</td>
<td>7.02%</td>
</tr>
<tr>
<td>Gap</td>
<td>Neutral</td>
<td>2.93%</td>
<td>$1.58B</td>
<td>9.08%</td>
</tr>
<tr>
<td>Abercrombie &amp; Fitch</td>
<td>Neutral</td>
<td>21.24%</td>
<td>$736.26M</td>
<td>11.65%</td>
</tr>
<tr>
<td>Boot Barn Holdings</td>
<td>Buy</td>
<td>13.71%</td>
<td>$152.86M</td>
<td>2.94%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Burlington Stores ranks at the top for Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, it is at the bottom compared to its peers.</p>
<h3>Discovering Burlington Stores: A Closer Look</h3>
<p>Burlington Stores Inc is off-price retailer offering an extensive selection of in-season, fashion-focused merchandise including: women's ready-to-wear apparel, menswear, youth apparel, baby, beauty, footwear, accessories, home, toys, gifts and coats. Company sell a broad selection of desirable, first-quality, current-brand, labeled merchandise acquired directly from nationally recognized manufacturers and other suppliers. Company sell product in category such as Ladies apparel, Accessories and shoes, Home, Mens apparel, Kids apparel and baby and Outerwear.</p>
<h3>Financial Insights: Burlington Stores</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Growth:</strong> Burlington Stores displayed positive results in 3 months. As of 31 July, 2024, the company achieved a solid revenue growth rate of approximately <strong>13.37%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Burlington Stores's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>2.99%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Burlington Stores's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>7.02%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Burlington Stores's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.95%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>4.5</strong>, caution is advised due to increased financial risk.</p>
<p><a href="https://www.benzinga.com/quote/BURL/earnings"><strong>To track all earnings releases for Burlington Stores visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


BURL

A Peek at Burlington Stores's Future Earnings

<p>Canadian Natural Res (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNQ#NYSE">CNQ</a>) has outperformed the market over the past 5 years by 6.39% on an annualized basis producing an average annual return of 20.03%. Currently, Canadian Natural Res has a market capitalization of $73.54 billion. </p>
<p><strong>Buying $1000 In CNQ:</strong> If an investor had bought $1000 of CNQ stock 5 years ago, it would be worth <strong>$2,491.24</strong> today based on a price of $34.80 for CNQ at the time of writing.</p>
<h3>Canadian Natural Res's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732543250_0_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,500 Today

<p>Marsh &amp; McLennan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) has outperformed the market over the past 5 years by 2.45% on an annualized basis producing an average annual return of 16.09%. Currently, Marsh &amp; McLennan has a market capitalization of $112.78 billion. </p>
<p><strong>Buying $1000 In MMC:</strong> If an investor had bought $1000 of MMC stock 5 years ago, it would be worth <strong>$2,108.08</strong> today based on a price of $229.63 for MMC at the time of writing.</p>
<h3>Marsh &amp; McLennan's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732543245_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today

<p>6 analysts have expressed a variety of opinions on NIO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $5.93, with a high estimate of $8.00 and a low estimate of $3.90. Observing a downward trend, the current average is 1.82% lower than the prior average price target of $6.04. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732543244_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A comprehensive examination of how financial experts perceive NIO is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tina Hou</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$3.90</td>
<td>$4.80</td>
</tr>
<tr>
<td>Eugene Hsiao</td>
<td>Macquarie</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$4.80</td>
<td>$6.60</td>
</tr>
<tr>
<td>Eugene Hsiao</td>
<td>Macquarie</td>
<td>Announces</td>
<td>Outperform</td>
<td>$6.60</td>
<td>-</td>
</tr>
<tr>
<td>Nick Lai</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$5.30</td>
</tr>
<tr>
<td>Ming Hsun Lee</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$5.30</td>
<td>$5.00</td>
</tr>
<tr>
<td>Jeff Chung</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$7.00</td>
<td>$8.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NIO. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of NIO compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for NIO's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of NIO's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NIO/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on NIO analyst ratings.</strong></a></p>
<h2>Discovering NIO: A Closer Look</h2>
<p>Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold over 160,000 EVs in 2023, accounting for about 2% of the China passenger new energy vehicle market.</p>
<h3>NIO: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Negative Revenue Trend:</strong> Examining NIO's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately <strong>-2.06%</strong> in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> NIO's net margin is impressive, surpassing industry averages. With a net margin of <strong>-27.53%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> NIO's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-37.5%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> NIO's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-5.03%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>2.99</strong>, caution is advised due to increased financial risk.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Unveiling 6 Analyst Insights On NIO

<p>H World Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTHT#NASDAQ">HTHT</a>) is preparing to release its quarterly earnings on Tuesday, 2024-11-26. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect H World Group to report an <strong>earnings per share</strong> (EPS) of $0.65.</p>
<p>The market awaits H World Group's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS missed by $0.21 in the last quarter, leading to a 3.07% increase in the share price on the following day.</p>
<p>Here's a look at H World Group's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.74</td>
<td>0.28</td>
<td>0.36</td>
<td>0.43</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.53</td>
<td>0.34</td>
<td>0.29</td>
<td>0.58</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>3.0%</td>
<td>-2.0%</td>
<td>-5.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732543241_0.png" alt="eps graph" /></p>
<h3>Market Performance of H World Group's Stock</h3>
<p>Shares of H World Group were trading at $35.8 as of November 22. Over the last 52-week period, shares are down 2.51%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/HTHT/earnings"><strong>To track all earnings releases for H World Group visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


HTHT

Examining the Future: H World Group's Earnings Outlook

<p>Wingstop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) has outperformed the market over the past 5 years by 19.74% on an annualized basis producing an average annual return of 33.37%. Currently, Wingstop has a market capitalization of $9.86 billion. </p>
<p><strong>Buying $1000 In WING:</strong> If an investor had bought $1000 of WING stock 5 years ago, it would be worth <strong>$4,220.00</strong> today based on a price of $337.60 for WING at the time of writing.</p>
<h3>Wingstop's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732543239_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


WING

Here's How Much $1000 Invested In Wingstop 5 Years Ago Would Be Worth Today

<p>HP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) is gearing up to announce its quarterly earnings on Tuesday, 2024-11-26. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that HP will report an <strong>earnings per share</strong> (EPS) of $0.93.</p>
<p>Anticipation surrounds HP's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Historical Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS missed by $0.03, leading to a 2.01% increase in the share price on the subsequent day.</p>
<p>Here's a look at HP's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.86</td>
<td>0.81</td>
<td>0.81</td>
<td>0.9</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.83</td>
<td>0.82</td>
<td>0.81</td>
<td>0.9</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>17.0%</td>
<td>-1.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732543232_0.png" alt="eps graph" /></p>
<h3>Market Performance of HP's Stock</h3>
<p>Shares of HP were trading at $38.13 as of November 22. Over the last 52-week period, shares are up 33.14%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/HPQ/earnings"><strong>To track all earnings releases for HP visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Insights into HP's Upcoming Earnings

<p>In the last three months, 10 analysts have published ratings on Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Guess, presenting an average target of $27.5, a high estimate of $29.00, and a low estimate of $21.00. This current average has decreased by 5.17% from the previous average price target of $29.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732543230_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Guess. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Mauricio Serna</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$21.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Lowers</td>
<td>Buy</td>
<td>$29.00</td>
<td>$37.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Guess. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Guess compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Guess's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Capture valuable insights into Guess's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/GES/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Guess analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Get to Know Guess Better</h2>
<p>Guess? Inc designs, markets distributes, and licenses contemporary apparel and accessories that reflect European fashion sensibilities and American Lifestyle under brands including Guess, Marciano, and G by Guess. The company has five reportable segments: Americas Retail, Americas Wholesale, Europe, Asia, and licensing. Geographically, the company derives maximum revenue from the United States.</p>
<h3>Guess's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Guess's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>10.24%</strong> as of 31 July, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Guess's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-1.47%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Guess's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-2.04%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Guess's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-0.39%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>2.86</strong>, caution is advised due to increased financial risk.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Comments

HAEMATO

News

Latest news for HAEMATO (OTC:HAAGF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga